Characterization of [ <sup> <b>18</b> </sup> F]PF-NB1 Enantiomers for Imaging NMDA GluN2B Receptors in Nonhuman Primates and Comparison with Analogous <sup> <b>18</b> </sup> F-labeled Radiotracers

The GluN2B subunit of <i>N</i>-methyl-d-aspartate receptors (NMDARs) plays a key role in regulating excitatory neurotransmission and synaptic plasticity. Aberrant GluN2B signaling contributes to glutamate-mediated excitotoxicity and has been implicated in neurodegenerative and neuropsychiatric disorders, making it a crucial target for therapeutic development and <i>in vivo</i> imaging. In this study, we systematically evaluated the pharmacokinetics and imaging characteristics of both (<i>R</i>)- and (<i>S</i>)-enantiomers of [<sup>18</sup>F]PF-NB1 PET tracers in nonhuman primates to determine their suitability for clinical translation. Dynamic PET scans, arterial input functions, kinetic modeling, and blocking studies were performed to assess brain uptake, regional distribution consistent with GluN2B expression, binding specificity, and metabolite profiles. In addition to direct comparison of the two enantiomers, we benchmarked their in vivo performance against analogous <sup>18</sup>F-labeled GluN2B tracers, including OF-Me-NB1 and OF-NB1. This cross-evaluation revealed differences in brain uptake, regional distribution matching GluN2B expression, binding specificity, and metabolic stability. Regional time-activity curves were fitted with the one-tissue compartment (1TC) model to derive regional volume of distribution (<i>V</i><sub>T</sub>) values, which were higher for (<i>R</i>)-[<sup>18</sup>F]PF-NB1(61.5-169.4 mL/cm<sup>3</sup>) than (<i>S</i>)-[<sup>18</sup>F]PF-NB1 (48.6-88.9 mL/cm<sup>3</sup>) in the same monkey. A GluN2B selective antagonist, Co-101,244, substantially reduced the uptake and <i>V</i><sub>T</sub> values of both (<i>R</i>)- and (<i>S</i>)-[<sup>18</sup>F]PF-NB1 across brain regions, with calculated target occupancy of 96% and 90%, and nondisplaceable volume of distribution (<i>V</i><sub>ND</sub>, mL/cm<sup>3</sup>) values of 10.01 and 11.45, respectively. In the same monkey, regional nondisplaceable binding potential (<i>BP</i><sub>ND</sub>) values ranged from 3.24 to 6.76 for (<i>S</i>)-[<sup>18</sup>F]PF-NB1, and from 5.12 to 15.92 for (<i>R</i>)-[<sup>18</sup>F]PF-NB1.

Authors

Institutions

Publication Details

Journal
ACS Chemical Neuroscience
Published
2025-12-15
DOI
https://doi.org/10.1021/acschemneuro.5c00840
Primary Topic
Neuroscience and Neuropharmacology Research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Characterization of [ 18 F]PF-NB1 Enantiomers for Imaging NMDA GluN2B Receptors in Nonhuman Primates and Comparison with Analogous 18 F-labeled Radiotracers

Santosh Reddy Alluri, Daniel Holden, Richard E. Carson, Yiyun Huang et al.
ACS Chemical Neuroscience
Neuroscience and Neuropharmacology Research
article

Characterization of [ 18 F]PF-NB1 Enantiomers for Imaging NMDA GluN2B Receptors in Nonhuman Primates and Comparison with Analogous 18 F-labeled Radiotracers

Santosh Reddy Alluri, Daniel Holden, Richard E. Carson, Yiyun Huang, Simon M. Ametamey, Michael Kapinos, Zachary Felchner, Hazem Ahmed, Ming‐Qiang Zheng
article en

Abstract

The GluN2B subunit of <i>N</i>-methyl-d-aspartate receptors (NMDARs) plays a key role in regulating excitatory neurotransmission and synaptic plasticity. Aberrant GluN2B signaling contributes to glutamate-mediated excitotoxicity and has been implicated in neurodegenerative and neuropsychiatric disorders, making it a crucial target for therapeutic development and <i>in vivo</i> imaging. In this study, we systematically evaluated the pharmacokinetics and imaging characteristics of both (<i>R</i>)- and (<i>S</i>)-enantiomers of [<sup>18</sup>F]PF-NB1 PET tracers in nonhuman primates to determine their suitability for clinical translation. Dynamic PET scans, arterial input functions, kinetic modeling, and blocking studies were performed to assess brain uptake, regional distribution consistent with GluN2B expression, binding specificity, and metabolite profiles. In addition to direct comparison of the two enantiomers, we benchmarked their in vivo performance against analogous <sup>18</sup>F-labeled GluN2B tracers, including OF-Me-NB1 and OF-NB1. This cross-evaluation revealed differences in brain uptake, regional distribution matching GluN2B expression, binding specificity, and metabolic stability. Regional time-activity curves were fitted with the one-tissue compartment (1TC) model to derive regional volume of distribution (<i>V</i><sub>T</sub>) values, which were higher for (<i>R</i>)-[<sup>18</sup>F]PF-NB1(61.5-169.4 mL/cm<sup>3</sup>) than (<i>S</i>)-[<sup>18</sup>F]PF-NB1 (48.6-88.9 mL/cm<sup>3</sup>) in the same monkey. A GluN2B selective antagonist, Co-101,244, substantially reduced the uptake and <i>V</i><sub>T</sub> values of both (<i>R</i>)- and (<i>S</i>)-[<sup>18</sup>F]PF-NB1 across brain regions, with calculated target occupancy of 96% and 90%, and nondisplaceable volume of distribution (<i>V</i><sub>ND</sub>, mL/cm<sup>3</sup>) values of 10.01 and 11.45, respectively. In the same monkey, regional nondisplaceable binding potential (<i>BP</i><sub>ND</sub>) values ranged from 3.24 to 6.76 for (<i>S</i>)-[<sup>18</sup>F]PF-NB1, and from 5.12 to 15.92 for (<i>R</i>)-[<sup>18</sup>F]PF-NB1.

ACS Chemical NeuroscienceVol. 17(1)
Yale University (US), ETH Zurich (CH)
Openalex Percentile: Top 57%
Neuroscience and Neuropharmacology Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.